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Abstract: Sorafenib represents the standard of care for advanced hepatocellular carcinoma (HCC),
even though a large number of patients have reported limited efficacy. The aim of the present study
was to evaluate the prognostic value of single-nucleotide polymorphisms on angiopoietin-2 (ANGPT2)
and endothelial-derived nitric oxide synthase (NOS3) genes in 135 patients with advanced HCC
receiving sorafenib. Eight ANGPT2 polymorphisms were analyzed by direct sequencing in relation to
overall survival (OS) and progression-free survival (PFS). In univariate analysis, ANGPT2rs55633437
and NOS3 rs2070744 were associated with OS and PFS. In particular, patients with ANGPT2rs55633437
TT/GT genotypes had significantly lower median OS (4.66 vs. 15.5 months, hazard ratio (HR) 4.86,
95% CI 2.73–8.67, p < 0.001) and PFS (1.58 vs. 6.27 months, HR 4.79, 95% CI 2.73–8.35, p < 0.001) than
those homozygous for the G allele. Moreover, patients with NOS3 rs2070744 TC/CC genotypes had
significantly higher median OS (15.6 vs. 9.1 months, HR 0.65, 95% CI 0.44–0.97; p = 0.036) and PFS
(7.03 vs. 3.5 months, HR 0.43, 95% CI 0.30–0.63; p < 0.001) than patients homozygous for the T allele.
Multivariate analysis confirmed these polymorphisms as independent prognostic factors. Our results
Cancers 2019, 11, 1023; doi:10.3390/cancers11071023 www.mdpi.com/journal/cancers
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suggest that ANGPT2rs55633437 and NOS3 rs2070744 polymorphisms could identify a subset of HCC
patients more resistant to sorafenib.
Keywords: single-nucleotide polymorphism; angiopoietin; endothelial nitric oxide synthase;
hepatocellular carcinoma; biomarkers; angiogenesis; Child–Pugh; VEGF
1. Introduction
Primary liver cancer represents the sixth most common cancer and the third most frequent cause
of cancer-related death worldwide [1]. Hepatocellular carcinoma (HCC) is the most common type of
primary liver cancer, and despite new therapeutic approaches, prognosis remains poor.
Patients with advanced-stage disease can benefit from systemic therapies. Sorafenib, a multi-target
tyrosine kinase inhibitor, has been considered the standard of care for patients with advanced
unresectable HCC since 2007 [2], but it is expensive and associated with adverse events (AEs).
Furthermore, a proportion of patients show no response to sorafenib, and molecular predictors of its
efficacy have not yet been identified [3].
Moreover, given the prominent arrival of new drugs in this setting [4], it would be useful to have
biomarkers capable of identifying those patients who are more likely to benefit from certain therapies.
Angiogenesis is one of the pathways most involved in the mechanism of action of sorafenib, and
numerous studies have focused on the role of markers involved in the angiogenesis process at both the
expression and genetic levels [3,5]. The largest biomarker study conducted to date is the SHARP trial,
in which baseline angiopoietin-2 (Ang-2) plasma levels independently predicted survival in both the
entire patient population and the placebo cohort [5].
Ang-2 is an angiogenic factor that binds Tie2 receptor and cooperates with the vascular endothelial
growth factor (VEGF) pathway to maintain physiological functions. Genetic variants in the Ang-2
gene (ANGPT2) may lead to altered activities of the gene.
In our previous retrospective study, we analyzed three endothelium-derived nitric oxide synthase
(NOS3) polymorphisms located inside theNOS3 gene on chromosome 7. We demonstrated that patients
with the NOS3 rs2070744 (NOS3-786) TT genotype had significantly shorter median progression-free
survival (PFS) and overall survival (OS) when compared to those with other genotypes [6].
The primary aim of the current study was to investigate the prognostic value of different
single-nucleotide polymorphisms (SNPs) on ANGPT2 and NOS3 genes in relation to OS in patients
with advanced HCC receiving sorafenib treatment. The second aim was to verify whether these
polymorphisms are related or not to progression-free survival (PFS), disease control rate (DCR),
and toxicities.
2. Results
2.1. Patient Characteristics and Clinical Variables
The main clinical pathological characteristics of patients are shown in Table 1. The median
follow-up for PFS was 2.96 months (95% CI: 1.87–3.91), whereas that for OS was 8.9 months (1.71–48.92).
The median PFS was 5.75 months (95% CI: 5.06–6.60), and the median OS was 14.39 months (95% CI:
11.83–15.74).
Univariate analyses regarding PFS and OS data in relation to baseline patient characteristics are
shown in Table 2. In particular, we found that patients with hepatitis B virus (HBV) etiology showed
worse OS than patients with hepatitis C virus (HCV) etiology (8.57 vs. 14.3 months; hazard ratio (HR)
1.95, 95% CI: 1.17–3.26; p = 0.011), and patients without extra-hepatic spread showed better outcomes
in terms of PFS (6.27 vs. 2.83 months; HR 0.50, 95% CI: 0.34–0.73; p < 0.001) and OS (15.6 vs. 10.84
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months; HR 0.65, 95% CI: 0.43–0.99; p = 0.043) than patients with metastatic disease. No significant
correlation was found between the other clinical characteristics and clinical outcomes.
Table 1. Patient characteristics.
Clinical and Pathologic Variables No. (%)
Median age at start of treatment
(min–max) 70 (25–88)
Gender
Male 109 (80.7)
Female 26 (19.3)
Etiology
Metabolic syndrome 18 (13.3)
Alcoholic 10 (7.4)
Viral—HBV 22 (16.3)
Viral—HCV 78 (57.8)
Cryptogenic 7 (5.2)
BCLC stage
B 37 (27.4)
C 98 (72.6)
Child–Pugh
A 125 (92.6)
B 10 (7.4)
ECOG Performance Status
0 83 (61.5)
1–2 52 (38.5)
Sorafenib dose reduction
No 59 (61.5)
Yes 37 (38.5)
Missing data 39
Extra-hepatic spread
No 81 (64.3)
Yes 45 (35.7)
Serum α-FP level
≤400 54 (40)
>400 35 (25.9)
Missing data 46
Abbreviations: BCLC, Barcelona Clinic Liver Cancer; ECOG, Eastern Cooperative Oncology Group; α-FP,
alpha-fetoprotein; HBV, hepatitis B virus; HCV, hepatitis C virus.
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Table 2. PFS and OS in relation to baseline patient characteristics.
Clinical and Pathologic Variables PFS OS
Median PFS [95% CI] HR [95% CI] p Median OS [95% CI] HR [95% CI] p
Gender
Female 6.11 [3.22–8.18] 1 12.35 [5.72–20.89] 1
Male 5.62 [5.03–6.27] 0.96 [0.62–1.50] 0.873 14.85 [11.83–15.80] 0.94 [0.59–1.52] 0.814
Median age at start of treatment * 0.92 [0.85–0.995] 0.038 0.94 [0.87–1.02] 0.118
Etiology
Viral—HCV 6.11 [5.06–6.90] 1 14.29 [11.14–17.77] 1
Cryptogenic 3.98 [3.19–21.91] 0.96 [0.44–2.11] 0.926 16.43 [3.98–NR] 0.70 [0.29–1.76] 0.453
Alcoholic 5.26 [1.41–8.71] 0.98 [0.50–1.92] 0.956 14.39 [1.41–17.15] 1.23 [0.59–2.59] 0.580
Metabolic syndrome 6.01 [3.25–8.51] 1.21 [0.71–2.06] 0.478 15.64 [6.80–21.68] 1.11 [0.63–1.96] 0.710
Viral—HBV 5.06 [2.33–6.90] 1.45 [0.90–2.34] 0.131 8.57 [4.66–15.24] 1.95 [1.17–3.26] 0.011
Child–Pugh
A 5.75 [5.06–6.60] 1 14.59 [11.83–15.74] 1
B 6.11 [0.69–11.37] 0.76 [0.37–1.57] 0.459 13.53 [1.48–26.41] 1.16 [0.56–2.40] 0.683
BCLC
B 6.60 [5.06–8.77] 1 14.36 [11.24–16.43] 1
C 5.32 [4.11–6.14] 1.27 [0.86–1.88] 0.225 14.59 [9.99–16.43] 1.05 [0.68–1.62] 0.819
ECOG Performance Status
0 5.75 [5.03–6.60] 1 14.39 [11.7–15.74] 1
1–2 6.01 [2.69–7.42] 1.01 [0.71–1.45] 0.949 15.01 [8.18–18.92] 1.23 [0.84–1.80] 0.294
Extra-hepatic spread
Yes 2.83 [1.94–5.22] 1 10.84 [6.96–15.08] 1
No 6.27 [5.72–7.65] 0.50 [0.34–0.73] <0.001 15.60 [12.81–18.00] 0.65 [0.43–0.99] 0.043
Serum α-FP level
≤400 5.75 [3.75–6.64] 1 13.57 [10.35–16.66] 1
>400 5.72 [2.92–7.23] 0.87 [0.56–1.34] 0.526 13.86 [8.15–15.80] 1.26 [0.80–2.01] 0.320
* 5-year increment. Abbreviations: BCLC, Barcelona Clinic Liver Cancer; ECOG, Eastern Cooperative Oncology Group; α-FP, alpha-fetoprotein; PFS, progression-free survival; OS, overall
survival; HR, hazard ratio; HBV, hepatitis B virus; HCV, hepatitis C virus.
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2.2. ANGPT2 and NOS3 Genotypes and Clinical Outcomes
The genotype frequencies of ANGPT2 and NOS3 polymorphisms are shown in Table S1, and all
followed the Hardy–Weinberg equilibrium. Missing data on polymorphisms are due to the lack of
input DNA. Some ANGPT2 and NOS3 SNPs were highly correlated to each other (Table S2).
By univariate analysis we found that three ANGPT2 SNPs and two NOS3 SNPs were associated
with clinical outcomes. In particular, ANGPT2 SNP rs55633437 was associated with both PFS and
OS. For this polymorphism, we chose the dominant genetic model. Patients with at least one copy
of the minor allele T had significantly lower median PFS (1.58 vs. 6.27 months, HR 4.79, 95% CI
2.73–8.35; p < 0.001) and OS (4.66 vs. 15.51 months, HR 4.86, 95% CI 2.73–8.67; p < 0.001) than did
those homozygous for the G allele (Table 3 and Figure 1).
ANGPT2 rs3020221 and rs1961222 were associated only with OS. For rs3020221, we chose the
recessive genetic model, and patients homozygous for the A allele showed significantly better median
OS than did those with other genotypes (18.99 vs. 12.81 months, HR 0.53, 95% CI 0.31–0.92; p = 0.024)
(Table 3 and Figure 2a). For rs1961222, we chose the dominant genetic model, and patients carrying at
least one copy of the minor allele A showed significantly better median OS (16.43 vs. 11.24 months, HR
0.67, 95% CI 0.46–0.99; p = 0.044) than did those homozygous for the G allele (Table 3 and Figure 2b).
No statistically significant differences were observed for other ANGPT2 polymorphisms and PFS
and OS.
With regard to NOS3, we conducted an updated follow-up of our previously described case
series [6] and we added seven patients. By univariate analysis we confirmed that patients with at least
one copy of the minor allele C for NOS3 rs2070744T > C polymorphisms had a significantly better
outcome, with higher median PFS (7.03 vs. 3.5 months, HR 0.43, 95% CI 0.30–0.63; p < 0.001) and OS
(15.6 vs. 9.1 months, HR 0.65, 95% CI 0.44–0.97; p = 0.036) than those of patients homozygous for the T
allele (Table 3 and Figure 3).
Moreover, NOS3 VNTR4a/b patients with at least one copy of the minor allele “a” showed
significantly higher median PFS (7.65 vs. 5.06 months, HR 0.54, 95% CI 0.36–0.80; p = 0.002) than did
patients homozygous for the “b” allele (Table 3 and Figure 3).
No statistically significant differences were observed for the other NOS3 polymorphisms. For
ANGPT2 SNPs, rs55633437 was associated with extra-hepatic spread; in particular, 64% of patients
with at least one copy of the T allele presented with metastatic disease. Conversely, 32.7% of patients
homozygous for the G allele showed extra-hepatic spread. No significant association was found
between the main clinicopathological characteristics of patients and NOS3 polymorphisms (analyses
not shown).
Following adjustment for clinical covariates (age, etiology, and extra-hepatic spread), the final
model of multivariate analysis confirmed ANGPT2 rs55633437 and NOS3 rs2070744 as the independent
prognostic factors predicting PFS (HR 0.24, 95% CI 0.15–0.38, p < 0.001; HR 6.32, 95% CI 3.32–12.04,
p < 0.001, respectively) and OS (HR 0.67, 95% CI 0.47–0.96, p = 0.03; HR 5.48, 95% CI 2.85–10.54,
p < 0.001, respectively) (Table 4). Regarding the clinical parameters, extra-hepatic spread and HBV
etiology remained the independent prognostic factors predicting OS (Table 4).
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Table 3. Univariate analysis of PFS and OS in relation to ANGPT2 and NOS3 polymorphisms.
Gene Polymorphisms Genetic Model
PFS OS
Median PFS [95% CI] HR [95% CI] p Median OS [95% CI] HR [95% CI] p
ANGPT2
rs3739392 DOM
TT 5.62 [5.03–6.73] 1 14.39 [11.24–16.43] 1
CC/TC 6.14 [3.91–8.54] 0.94 [0.64–1.39] 0.765 13.57 [8.15–18.00] 0.92 [0.60–1.39] 0.679
rs3739391 DOM
CC 5.75 [5.06–6.90] 1 15.11 [12.65–18.50] 1
TT/CT 6.04 [3.91–6.80] 1.13 [0.79–1.63] 0.506 11.14 [8.54–15.64] 1.17 [0.79–1.73] 0.445
rs3739390 DOM
GG 5.75 [5.03–6.60] 1 14.36 [11.24–15.74] 1
CC/GC 6.27 [2.60–12.61] 0.83 [0.52–1.31] 0.416 12.81 [8.15–20.89] 0.88 [0.54–1.44] 0.621
rs55633437 DOM
GG 6.27 [5.75–7.23] 1 15.51 [13.57–18.40] 1
TT/GT 1.58 [0.76–3.32] 4.79 [2.73–8.35] <0.001 4.66 [2.69–8.57] 4.86 [2.73–8.67] <0.001
rs3020221 REC
GG/GA 5.78 [5.06–6.60] 1 12.81 [10.35–15.24] 1
AA 8.77 [4.01–10.78] 0.72 [0.45–1.14] 0.163 18.99 [13.57–36.47] 0.53 [0.31–0.92] 0.024
rs1961222 DOM
GG 5.32 [3.19–6.60] 1 11.24 [8.54–15.01] 1
AA /GA 6.04 [5.09–8.02] 0.93 [0.65–1.34] 0.712 16.43 [13.57–18.99] 0.67 [0.46–0.99] 0.044
rs17063434 DOM
TT 5.62 [5.03–6.14] 1 0.84 [11.99–17.77] 1
CC /TC 6.80 [6.14–8.54] 0.93 [0.55–1.56] 0.779 11.24 [8.15–15.64] 1.59 [0.94–2.69] 0.084
rs2916747
TT 5.78 [5.06–6.60] 1 14.39 [11.99–16.43] 1
TC 6.27 [1.97–13.83] 0.61 [0.34–1.10] 0.102 11.70 [4.20–27.79] 1.09 [0.61–1.94] 0.784
NOS3
NOS3 +894 (rs1799983) DOM
GG 5.22 [2.83–6.11] 1 15.74 [9.23–18.50] 1
GT/TT 6.60 [5.32–8.18] 0.81 [0.57–1.16] 0.251 14.29 [11.14–15.51] 1.14 [0.77–1.68] 0.527
VNTR4a4b DOM
4bb 5.06 [3.75–6.11] 1 11.99 [9.10–14.85] 1
4aa/4ab 7.65 [6.08–12.61] 0.54 [0.36–0.80] 0.002 17.15 [14.59–20.89] 0.68 [0.44–1.05] 0.080
NOS3-786 (rs2070744) DOM
TT 3.25 [2.33–5.06] 1 9.10 [6.80–14.29] 1
CC/TC 7.03 [6.08–8.67] 0.43 [0.30–0.63] <0.001 15.60 [13.86–19.51] 0.65 [0.44–0.97] 0.036
Abbreviations: DOM, dominant; REC; recessive; VNTR, variable number of tandem repeats; PFS, progression-free survival; OS, overall survival; HR, hazard ratio.
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Table 4. Multivariate analysis of OS.
Patient Characteristics HR [95% CI] p
Extra-hepatic spread
Yes 1
No 0.54 [0.35–0.84] 0.007
Etiology
Viral—HCV 1
Biliary cirrhosis/cryptogenic 0.33 [0.08–1.39] 0.131
Alcoholic 1.69 [0.75–3.84 0.207
Metabolic syndrome 1.50 [0.80–2.83] 0.209
Viral—HBV 2.42 [1.38–4.26] 0.002
NOS3-786 (rs2070744)
TT 1
CC/TC 0.67 [0.47–0.96] 0.030
ANGPT2 rs55633437
GG 1
TT/GT 5.48 [2.85–10.54] <0.001
2.3. ANGPT2 and NOS3 Genotypes and Disease Control Rate (DCR)
Four (3.96%) patients showed a complete response (CR), 28 (27.72%) showed a partial response
(PR), 34 (33.66%) showed stable disease (SD), and 35 (34.65) patients showed disease progression (PD).
For 44 patients, information about the response was not available due to the retrospective nature
of the study design. ANGPT2 and NOS3 polymorphisms were investigated in relation to the DCR.
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For ANGPT2 polymorphisms, patients carrying at least one copy of the minor allele T for rs55633437
showed a lower percentage of DCR at the first CT re-evaluation than did those carrying the GG
genotype (13.3% vs. 75.3%, respectively, p < 0.001). Patients carrying at least one copy of the minor
allele A for rs1961222 showed a higher percentage of DCR at the first CT re-evaluation than did those
carrying the GG genotype (75.4% vs. 48.8%, respectively; p = 0.007).
Regarding NOS3, patients carrying at least one copy of the minor allele C for NOS3 rs2070744
showed a higher percentage of DCR at the first CT re-evaluation than did those carrying the TT
genotype (81.1% vs. 48.8%, respectively; p = 0.001). No substantial differences were seen between
other SNPs and response.
2.4. ANGPT2 and NOS3 Genotypes and Toxicities
We also investigated the relationship between ANGPT2 and NOS3 polymorphisms and the main
toxicities (skin toxicity, asthenia, and diarrhea). We divided these toxicities into early (within a month
of sorafenib treatment) and late (after a month of treatment).
We found that ANGPT2 rs1961222 and rs17063434 were associated with late skin toxicity with
grade ≥ 2 (Common Terminology Criteria for Adverse Events (CTCAE) 4.0) (p = 0.030 and p = 0.003,
respectively) (Figure S1).
No significant associations were observed between other ANGPT2 polymorphisms and skin
toxicity, asthenia, and diarrhea (Figure S1).
We found also that NOS3 rs1799983 was associated with late skin toxicity (p = 0.021) and with a
higher grade (CTCAE 4.0) of this toxicity (p = 0.003).
2.5. Haplotypes Analysis and Clinical Outcomes
We observed linkage disequilibrium between ANGPT2 polymorphisms. Lewontin’s
disequilibrium coefficient (D’) and the correlation coefficient (r2) are reported in Figure S2.
We identified two blocks of SNPs using Haploview software version 4.2, and for both blocks we
identified a total of four haplotypes. For Block 1, including rs1961222 and rs3020221, the most frequent
haplotype was HT1 (G–G at rs302022/rs1961222) (57.1%), followed by HT4 (A–A) (38%), HT3 (A–G)
(5.2%), and HT2 (G–A) (1%).
For Block 2, including rs3739392, rs3739391, and rs3739390, the most frequent haplotype was HT1
(T–C–G at rs3739392/rs3739391/rs3739390) (80.2%), followed by HT4 (C–T–C) (9.1%), HT3 (C–T–G)
(6.3%), and HT2 (T–T–G) (4.4%).
Regarding Block 1, univariate analysis showed that patients carrying at least one copy of HT1 had
lower median OS than did those without any copies of HT1 (12.8 vs. 21.7 months; HR 1.75, 95%CI
1.04–2.95; p = 0.037) (Table S3). No statistically significant differences were observed for other ANGPT2
haplotypes of Block 1 in relation to PFS and OS (Table S3).
Interestingly, regarding Block 2, univariate analysis showed that patients carrying at least one
copy of HT2 had lower median PFS (5.03 vs. 6.04 months; HR 2.05, 95%CI 1.08–3.89; p = 0.027) and OS
(9.9 vs. 15.1 months; HR 2.71, 95%CI 1.37–5.38; p = 0.004) than did those without any copies of HT2
(Table S4 and Figure 4).
The final multivariable model including age, etiology, and extra-hepatic spread confirmed the
previously mentioned NOS3 and ANGPT2 polymorphisms and haplotype 2 (HT2) of Block 2 as
independent prognostic factors predicting PFS (HR 0.24, 95% CI 0.15–0.38, p < 0.001; HR 6.03, 95% CI
3.1–11.6, p < 0.001; HR 2.48, 95% CI 1.2–5.2, p = 0.015, respectively) and OS (HR 0.46, 95% CI 0.29–0.73,
p = 0.001; HR 4.88, 95% CI 2.99–11.5, p < 0.001; HR 2.30, 95% CI 1.02–5.2, p = 0.044, respectively).
Regarding the clinical parameters, extra-hepatic spread and HBV etiology remained the independent
prognostic factors predicting OS (Table S5).
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2.6. Clustering Analysis
Unsupervised clustering of patients based on ANGPT2 and NOS3 non-synonymous variant
profiles revealed two distinct groups: one exclusively characterized by variants in the regulatory region
of NOS3 (called “1”) and the other mainly affected by variations at the ANGPT2 5′ UTR (called “2”)
(Figure S3).
Forty-four (32.5%) patients belonged to Cluster 1 and another 44 (32.5%) to Cluster 2. The median
PFS was 6.1 months (95% CI 4.1–7.0) for patients of Cluster 2 and 7.4 months (95% CI 5.8–8.8) for
patients of Cluster 1 (HR 1.55, 95% CI 0.99–2.41; p = 0.051) (Figure S4). The median OS was 10.6 months
(95% CI 8.7–16.4) for patients of Cluster 2 and 17.2 months (95% CI 14.4–22.7) for patients of Cluster 1
(HR 1.74, 95% CI 1.08–2.80; p = 0.02) (Figure S4).
Following adjustment for clinical covariates (alpha-fetoprotein, extra-hepatic spread, and etiology),
multivariate analysis confirmed that variants in the regulatory region of NOS3 were independent
prognostic factors predicting OS (HR 0.44, 95% CI 0.23–0.82; p = 0.01).
3. Discussion
The present study analyzed ANGPT2 and NOS3 polymorphisms in relation to clinical outcome in
patients with advanced HCC receiving sorafenib. In particular, we found that patients with ANGPT2
rs55633437 TT/GT genotypes had significa tly lower median OS and PFS than di patients with other
genotypes, and we confirmed that atients with the NOS3 rs2070744 TT ge otype showe a worse
progn sis than did atients with other genotypes.
We also identified an ANGPT2 haplotype (c aracterized by ANGPT2 rs3739392, rs3739391, and
rs3739390) that was significantly associated with worse OS and PFS.
Moreover, e found that patients exclusively characterized by variants in the regulatory region of
NOS3 showed better prognosis than did patients affected by variations at the ANGPT2 5′UTR.
We also found that atie ts with HCV etiology and without extra-hepatic spread showed better
outcomes in terms of OS, in agreement with Bruix et al.’s pooled analysis [7,8]. They demonstrated that
the benefit of sorafenib is significantly higher in patients with disease confined to the liver (without
extra- epatic spread), with HCV, or with low NLR (neutrophil/lymphocyte ratio).
We also found that patients carrying at least one copy of the minor allele T for ANGPT2 rs55633437
and patients with NOS3 rs2070744 TT genotypes showed a lower percentage of DCR at the first CT
re-evaluation. Moreover, patients with other genotypes associated with better PFS and OS showed
higher response rates.
ANGPT2 rs55633437 and NOS3 rs2070744 polymorphisms could identify a group of patients more
resistant to sorafenib.
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Currently, the measurement of specific predictive biomarkers for cancer therapy is mandatory in
patients with various cancer types [9]. However, for HCC, no biomarkers are available in relation to
sorafenib efficacy [3].
In the literature, only few studies have identified possible predictive markers relating to sorafenib
in HCC patients. In the SHARP trial, Llovet and co-workers found that low VEGF-A and Ang-2
plasma baseline concentrations predicted survival in patients with advanced HCC and that high
baseline plasma Ang-2 levels were related with a more aggressive disease [5]. Ang-2 protein levels also
increased during treatment in their placebo group, whereas they remained constant during treatment
with sorafenib, reflecting the generally more favorable outcome of patients in the sorafenib-treated
group [5]. In agreement with Llovet’s study, Miyahara et al. reported that high baseline Ang-2 serum
levels were associated with poor outcome in advanced-HCC patients receiving sorafenib [10].
Other authors investigated some SNPs in relation to sorafenib treatment. In particular, Scartozzi
et al. in the ALICE-1 study [11] and Faloppi et al. in the ALICE-2 study [12] showed that SNPs in
the VEGF-A, VEGF-C, and HIF-1α genes were independent factors influencing PFS and OS in HCC
patients receiving sorafenib.
Our study demonstrated the role of ANGPT2 and NOS3 polymorphisms in relation to clinical
outcome in advanced-HCC patients receiving sorafenib.
The ANGPT2 gene is a highly polymorphic gene [13], and SNPs may alter gene expression [14].
Some SNPs have been studied in association with obstetric diseases, premature retinopathy, and acute
respiratory distress syndrome [15–17].
Some authors investigated the role of ANGPT2 variants in colorectal cancer patients with liver
metastases [18] or in breast cancer patients [19] in relation to bevacizumab-based treatment, but no
work has studied the impact of Ang-2 genetic variants in relation to treatment in HCC patients.
The functional role of our ANGPT2 polymorphisms are not well documented in the literature,
but SNP function prediction tools reveal that these SNPs could be located inside transcription factor
binding sites (TFBS) or exonic splicing enhancers/silencers (ESE or ESS). In particular, the three SNPs
of Block 2 (rs3739390, rs3739391, and rs3739392), located in the 5′ UTR region, could be found in a
transcription factor binding site and probably have an effect on protein synthesis.
In our study, ANGPT2 rs55633437 TT/GT genotypes and an ANGPT2 haplotype were associated
with lower median OS and PFS. Considering that increased Ang-2 expression levels were associated
with poorer outcome in previous studies [5,10], it is plausible that these kinds of variants are associated
with higher Ang2 protein levels.
Thus, it will be interesting to evaluate a correlation between the presence of a specific allele on a
polymorphic site and the expression of the respective protein.
ANGPT2 and NOS3 are not the direct target of sorafenib, and other factors may be involved in the
relation between Ang-2, NOS3 activity, and sorafenib efficacy. In particular, it is possible that these
genetic variants are linked with other functional variants in the regulatory regions of the ANGPT2 or
NOS3 genes.
With regard to toxicity, we found that ANGPT2 rs1961222 and rs17063434 and NOS3 rs1799983
were associated with late skin toxicity.
The development of dermatologic adverse events (DAEs) early (within the first 60 days of
treatment) after treatment initiation is associated with delayed tumor progression and improved
survival [20]. It was recently demonstrated that the angiotensinogen (AGT) M235T SNPs can predict
early DAEs in HCC patients treated with sorafenib [21].
The identification of predictive biomarkers for early DAEs would be important to defining a
population with a major survival impact by treatment.
It was shown that patients with hypertension during sorafenib treatment showed better PFS
and OS [22–24]. Unfortunately, we did not have available data about hypertension due to the
retrospective nature of the study, but given the possible correlation between NOS3 polymorphisms
and hypertension [25,26], it will be interesting to evaluate this in our ongoing prospective study [27].
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The study has some limitations, e.g., its retrospective nature (cases were, however, consecutively
selected, thus reducing potential bias). As a consequence, we were not able to collect detailed data on
toxicities, particularly on hypertension and on the neutrophil/lymphocyte ratio (NLR).
Other limitations are that this study was carried out on Caucasian individuals only and the lack
of a control arm without sorafenib. Thus, it is not possible to define the prognostic or predictive value
of ANGPT2 and NOS3 polymorphisms.
4. Materials and Methods
4.1. Patient Enrollment
This was a retrospective multicenter Italian study carried out on 135 HCC patients consecutively
treated at Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori and at the Universities of
Ancona, Milan, and Bari, from 2012 to 2015.
We considered patients with advanced or intermediate-stage HCC, diagnosed according to the
American Association for the Study of Liver Diseases (AASLD) guidelines, treated with sorafenib, and
refractory or no longer amenable to locoregional therapies. The eligibility criteria were the same as
those of Llovet’s study [2]. Sorafenib was administered according to the agreed schedule (400 mg
twice a day continuously), and dose modifications were applied when medically indicated. A CT/MRI
scan every 8 weeks or as clinically indicated was used to provide follow-up monitoring. The modified
Response Evaluation Criteria in Solid Tumors (mRECIST) was used to measure tumor response to
treatment [28].
Treatment with sorafenib was continued until disease progression, unacceptable toxicity, or death.
The study was approved by the Local Ethics Committees of each center and informed consent was
obtained from each patient for their biological material to be used for research purposes (CEIIAV
IRSTB051).
4.2. DNA Isolation and Genotyping
We performed ANGPT2 genotyping using DNA extracted from whole-blood samples.
Peripheral blood samples were collected in EDTA tubes, and genomic DNA was extracted from
200 µL of whole blood using a QIAamp DNA Minikit (Qiagen SPA, Milan, Italy) in accordance with
the manufacturer’s instructions. DNA quantity and quality were assessed by Nanodrop 1000 (Celbio,
Milan, Italy).
Genotyping was performed for eight ANGPT2 SNPs (rs3739390, rs3739391, rs3739391, rs55633437,
rs3020221, rs1961222, rs2916747, rs17063434) by standard PCR and direct sequencing analysis on an
ABI 3130 Genetic Analyzer (Applied Biosystems). Primer sequences and PCR conditions are reported
in Table S6. PCRs were performed starting from 50 ng of genomic DNA.
We selected these polymorphisms through a review of the Single Nucleotide Polymorphism
database (dbSNP) (http://www.ncbi.nlm.nih.gov/SNP) and of medical literature.
Three SNPs (rs3739390, rs3739391, and rs3739392), located in the 5′ UTR region, were found
in a transcription factor binding site and could affect gene transcription. ANGPT2 rs55633437,
rs3020221, rs1961222, rs2916747, and rs17063434 are synonymous variants located inside exonic
splicing enhancers/silencers and they could affect gene transcription and splicing.
Polymorphism selection was done by also considering a minor allele frequency (MAF) above 5%
(with only the exception of rs17063434).
The selection of three NOS3 polymorphisms (NOS3 rs2070744; VNTR 4a/b and NOS3 rs1799983)
and genotyping analyses of these were described in our previous study [6].
The localizations and refSNP (rs) numbers of these polymorphisms are shown in Figure S5.
All analyses were centralized at Biosciences Laboratory, IRST IRCCS (Meldola, Italy), and
laboratory personnel were blinded to patient status when performing genotyping.
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4.3. Statistical Analysis
Data were summarized as median, minimum, and maximum values for continuous variables
and as absolute frequencies and percentages for categorical variables. The association between SNPs
and patients or clinical categorical variables was assessed by means of chi-squared test or Fisher’s
exact test, when appropriate, and among patients and clinical continuous variables by means of
Wilcoxon–Mann–Whitney testing.
The two main time-to-event end-points considered were progression-free survival (PFS), defined
as the time since the beginning of the treatment with sorafenib until disease progression or death
by any cause (whichever occurred first), and overall survival (OS), defined as the time since start of
treatment with sorafenib until death by any cause. Patients not experiencing the event of interest were
censored at the last follow-up available.
The disease control rate (DCR) was defined as the proportion of patients with a complete or partial
response or with stable disease. Pearson’s chi-squared test or Fisher’s exact test was used to evaluate
the association between SNPs and DCR or toxicity, when appropriate.
The Kaplan–Meier (KM) method and log-rank test were used to compare PFS and OS between
groups of patients. The median follow-up was computed on censored observations only. The median
PFS and OS values and corresponding 95% confidence intervals (CIs) are reported.
SNPs were prescreened prior to statistical analyses to determine the correct genetic model by
analyzing the Kaplan–Meier curves, following the approach by Savas et al. [29]. When the number of
patients with the minor allele homozygous genotype (n ≤ 10) was not sufficient, the dominant genetic
model was considered.
Hazard ratios (HRs) were estimated by means of the Cox proportional hazards regression
model. The proportional hazard assumption was assessed graphically and the test was based on
Schoenfeld residuals. Hardy–Weinberg equilibrium, linkage disequilibrium, and haplotype analyses
were performed using the Haploview v. 4.2 software package [30]. The software presents Lewontin’s
disequilibrium coefficient (D’), defined as a nonrandom association of alleles at two or more loci. The
D’ coefficient is equal to 1 only if there is a perfect linkage disequilibrium (LD). Haplotype blocks
were found using the Haploview v. 4.2 software package using the algorithm by Gabriel et al. [31].
The association between haplotypes and PFS or OS was found by means of the weighted haplotype
combination method proposed by French et al. [32] using a dominant model due to low frequencies.
To select the variables to include in the final Cox models, one for PFS and one for OS, we proceeded
as follows: we considered those variables significantly associated at the 10% level by univariate analysis
in addition to SNPs found to be significantly associated at the level of 10% by univariate analysis or
after adjustment for clinical covariates. Moreover, correlation among variables, especially among SNPs,
was taken into consideration during variable selection. SNP correlation was measured by estimating
tetrachoric correlation coefficients.
All statistical analyses were performed using STATA 15.0 statistical software (StataCorp, College
Station, TX, USA), version 3.4.1.
4.4. Clustering Analysis Method
We annotated variants using Variant Effect Predictor (VEP) [33]. We clustered patients according
to the non-synonymous variant profiles (ANGPT2 rs3739390, rs3739391, rs3739391, NOS3 rs2070744;
VNTR 4a/b) by assigning a numerical value of 1 or 2 if heterozygous or homozygous for a given
variant and 0 otherwise. Based on these numerical profiles, we calculated the distance between each
patient and clustered them using a full linkage hierarchical algorithm. The pdist and linkage functions
of scipy (https://www.scipy.org/) and the matplotlib python libraries were used for clustering and
drawing, respectively.
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5. Conclusions
In conclusion, our results suggest that the NOS3 rs2070744 and ANGPT2 rs55633437
polymorphisms and the presence of an ANGPT2 haplotype may be capable of identifying a subset of
HCC patients who are more resistant to sorafenib in terms of OS, PFS, and DCR. These data will be
confirmed in our ongoing multicenter prospective study (NCT02786342).
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/7/1023/s1,
Figure S1: Relationship between ANGPT2 polymorphisms and the main toxicities, Figure S2: Haploview
linkage disequilibrium plot and identification of haplotype block in the ANGPT2 gene, Figure S3: Clustering
of non-synonymous variants, Figure S4: Kaplan–Meier curves in accordance with non-synonymous variant
clusters, Figure S5: ANGPT2 and NOS3 polymorphisms, Table S1: Genotype frequencies of ANGPT2 and NOS3
polymorphisms, Table S2: Correlation coefficient between polymorphisms, Table S3: Univariate analysis of PFS
and OS in relation to Block 1 ANGPT2 haplotypes, Table S4: Univariate analysis of PFS and OS in relation to Block
2 ANGPT2 haplotypes, Table S5: Multivariate analysis of OS, considering NOS3, ANGPT2 SNPs and haplotypes,
Table S6: Primer sequences for ANGPT2 SNPs and PCR programs.
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